Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5 | European Medicines Agency

Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5 | European Medicines Agency

EMA’s human medicines committee (CHMP) has recommended authorising an adapted Comirnaty vaccine targeting the Omicron XBB.1.5 subvariant.

The vaccine – known as Comirnaty Omicron XBB.1.5 – is to be used for preventing COVID-19 in adults and children from 6 months of age. (...)